Unknown

Dataset Information

Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?


ABSTRACT: INTRODUCTION: Receptor tyrosine kinases (RTKs) are validated targets for oncology drug discovery and several RTK antagonists have been approved for the treatment of human malignancies. Nonetheless, the discovery and development of RTK antagonists has lagged behind the discovery and development of agents that target G-protein coupled receptors. In part, this is because it has been difficult to discover analogs of naturally-occurring RTK agonists that function as antagonists. AREAS COVERED: Here we describe ligands of ErbB receptors that function as partial agonists for these receptors, thereby enabling these ligands to antagonize the activity of full agonists for these receptors. We provide insights into the mechanisms by which these ligands function as antagonists. We discuss how informati

SUBMITTER: Riese DJ 

PROVIDER: S-EPMC3083243 | biostudies-literature | 2011 Feb

REPOSITORIES: biostudies-literature